BTIG Research upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.
Several other equities research analysts have also weighed in on GLX. Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th. Benchmark raised Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st.
View Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- Traders Started Betting on PayPal’s Rally Again
- Top Biotech Stocks: Exploring Innovation Opportunities
- Is BlackRock Signaling a Market Rally Despite New Tariffs?
- Why is the Ex-Dividend Date Significant to Investors?
- Microsoft: A Blend of Growth and Value Amid Tariff Concerns
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
